Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
Yamamoto S, Iihara H, Uozumi R, Kawazoe H, Tanaka K, Fujita Y, Abe M, Imai H, Karayama M, Hayasaki Y, Hirose C, Suda T, Nakamura K, Suzuki A, Ohno Y, Morishige KI, Inui N. Yamamoto S, et al. Among authors: hirose c. BMC Cancer. 2022 Mar 23;22(1):310. doi: 10.1186/s12885-022-09392-9. BMC Cancer. 2022. PMID: 35321690 Free PMC article. Clinical Trial.
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Hayashi H, Kita Y, Iihara H, Yanase K, Ohno Y, Hirose C, Yamada M, Todoroki K, Kitaichi K, Minatoguchi S, Itoh Y, Sugiyama T. Hayashi H, et al. Among authors: hirose c. Biomed Chromatogr. 2016 Jul;30(7):1150-1154. doi: 10.1002/bmc.3642. Epub 2015 Dec 1. Biomed Chromatogr. 2016. PMID: 26525154
Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy.
Kaito D, Iihara H, Funaguchi N, Endo J, Ito F, Yanase K, Toyoshi S, Sasaki Y, Hirose C, Arai N, Kitahora M, Ohno Y, Itoh Y, Minatoguchi S. Kaito D, et al. Among authors: hirose c. Anticancer Res. 2017 Apr;37(4):1965-1970. doi: 10.21873/anticanres.11537. Anticancer Res. 2017. PMID: 28373467
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H, Shimokawa M, Gomyo T, Fujita Y, Yoshida T, Funaguchi N, Minato K, Kaito D, Osawa T, Yamada M, Hirose C, Suzuki A, Ohno Y. Iihara H, et al. Among authors: hirose c. BMJ Open. 2019 Jul 4;9(7):e028056. doi: 10.1136/bmjopen-2018-028056. BMJ Open. 2019. PMID: 31278102 Free PMC article. Clinical Trial.
Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy.
Hirose C, Fujii H, Iihara H, Ishihara M, Nawa-Nishigaki M, Kato-Hayashi H, Ohata K, Sekiya K, Kitahora M, Matsuhashi N, Takahashi T, Okuda K, Naruse M, Ishihara T, Sugiyama T, Yoshida K, Suzuki A. Hirose C, et al. Support Care Cancer. 2020 Dec;28(12):5943-5952. doi: 10.1007/s00520-020-05443-8. Epub 2020 Apr 12. Support Care Cancer. 2020. PMID: 32281034 Free PMC article.
104 results